The World Health Organization (WHO) has approved the use of an mpox vaccine for the first time, which it says should facilitate “timely and increased access” for millions at risk in Africa where the latest outbreak has infected more than 20,000 so far this year.
The MVA-BN vaccine from the Danish pharmaceutical company Bavarian Nordic was prequalified by the WHO on Friday and has already been approved in Europe and the United States, for use by adults.
WHO approval will accelerate access for millions, to reduce transmission and help contain the outbreak.
WHO’s Director-General, Tedros Adhanom Ghebreyesus said the prequalification of this vaccine is an important step in the fight against the mpox virus in Africa and for the future.
“We now need urgent scale up in procurement, donations and rollout to ensure equitable access to vaccines where they are needed most, alongside other public health tools, to prevent infections, stop transmission and save lives,” Mr. Ghebreyesus said.
Vaccine administration
The MVA-BN vaccine can be given in two doses to people 18 years and older, four weeks apart, which has an estimated 82 per cent effectiveness.
For infants, young children, pregnant women and immunocompromised people, the vaccine may be used in situations where the benefits of the vaccine are greater than potential risks.
In instances where the vaccine supply is limited, the health organization recommends distribution in single doses, which is 76 per cent effective.
WHO said prequalification of the vaccine will help accelerate procurement by governments and international agencies such as vaccine alliance Gavi and UN Children’s Fund (UNICEF).
It can also help fast-track regulatory approval by countries worldwide.
What is mpox?
Formerly known as monkeypox, the viral disease can spread between people, mainly through close contact, and occasionally from the environment to people via objects and surfaces that have been touched by a person with mpox.
Originating in the Democratic Republic of the Congo in 1970, mpox was neglected there, according to WHO.
“It is time to act decisively to prevent history from repeating itself,” said Dimie Ogoina, who chairs the International Health Regulations’ Emergency Committee, which advises WHO on such matters.
Endemic in central and West Africa, the infectious disease later caused a global outbreak in 2022, leading to a WHO public health emergency in July as it became a multi-country outbreak.
Following a series of consultations with global experts, WHO has begun using a new preferred term “mpox” as a synonym for monkeypox.
What are the symptoms?
Common symptoms of mpox include a rash lasting for two to four weeks, which may be started with or followed by fever, headache, muscle aches, back pain, low energy and swollen lymph nodes.
The rash looks like blisters and can affect the face, palms of the hands, soles of the feet, groin, genital and/or anal regions, mouth, throat or the eyes. The number of sores can range from one to several thousand.
People with mpox are considered infectious at least until all their blisters have crusted over, the scabs have fallen off and a new layer of skin has formed underneath, and all lesions on the eyes and in the body have healed. Typically this takes two to four weeks. Reports show that people can be re-infected after they’ve had mpox.
People with severe mpox may require hospitalisation, supportive care and antiviral medicines to reduce the severity of lesions and shorten time to recovery.
How does mpox spread?
Human to human: Touching, sex and talking or breathing close to someone with mpox can generate infectious respiratory particles, but more research is needed on how the virus spreads during outbreaks in different settings and conditions, says WHO.
What scientists do know is that it is also possible for the virus to persist for some time on clothing, bedding, towels, objects, electronics and surfaces that have been touched by a person with mpox. Someone else who is in contact with these items may become infected without first washing their hands before touching their eyes, nose and mouth.
The virus can also spread during pregnancy to the fetus, during or after birth through skin-to-skin contact, or from a parent with mpox to an infant or child during close contact.
Although getting mpox from someone who is asymptomatic has been reported, there is still limited information on whether the virus can be transmitted from someone with the virus before they get symptoms or after their lesions have healed.
Humans to animals: Since many species of animals are known to be susceptible to the virus, there is the potential for spillback of the virus from humans to animals in different settings.
People who have confirmed or suspected mpox should avoid close physical contact with animals, including such pets as cats, dogs, hamsters and gerbils, as well as livestock and wildlife.
Animals to humans: Someone who comes into physical contact with an animal which carries the virus, such as some species of monkey – or a terrestrial rodent like a tree squirrel – may also develop mpox. Such exposure can occur through bites or scratches, or during activities such as hunting, skinning, trapping or preparing a meal. The virus can also be caught through eating contaminated meat which is not cooked thoroughly.
Can it be fatal?
Yes, for a small minority. Between 0.1 per cent and 10 per cent of people who have become infected with mpox, have died.
It is important to note that death rates in different settings may differ due to several factors, such as access to health care and underlying immunosuppression, including because of undiagnosed HIV or advanced HIV, according to the UN health agency.
In most cases, the symptoms of mpox go away on their own within a few weeks with supportive care, such as medication for pain or fever, but, in some people, the illness can be severe or lead to complications and eventual death.
Newborn babies, children, people who are pregnant and people with underlying immune deficiencies – such as from advanced HIV – may be at higher risk of more serious mpox disease and death.
